Shares of Tempus AI (TEM) plummeted 13.78% in Monday's after-hours trading session, following the company's release of disappointing fourth-quarter results and wider-than-expected annual losses for 2024.
The precision medicine technology firm reported Q4 revenue of $200.7 million, up 35.8% year-over-year, but missed analyst estimates of $203.1 million. For the full year 2024, revenue increased 30.4% to $693.4 million, driven by strong growth in both the Genomics and Data and Services segments.
However, Tempus AI's Q4 adjusted net loss widened to $0.18 per share from $0.15 per share a year earlier, missing analyst expectations of a $0.16 loss. The company reported a net loss of $705.8 million for the full year, significantly wider than the $214.1 million loss in 2023, largely due to $547.7 million in stock-based compensation expenses.
The wider-than-expected losses overshadowed Tempus AI's solid revenue growth and operational achievements in 2024, such as the acquisition of Ambry Genetics and the launch of FDA-approved diagnostic products. While the company raised its 2025 revenue guidance to $1.24 billion, representing 79% annual growth, and expects to achieve positive adjusted EBITDA of $5 million, investors appear concerned about the company's ability to rein in losses and achieve profitability.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.